StimOxyGen Raises £1.5m to Combat Cancer Therapy Resistance
Deal News | Mar 11, 2025 | DSW Ventures
StimOxyGen, a spin-out from Ulster University, has successfully secured £1.5 million in funding to expedite its innovative approach to overcoming cancer treatment resistance in solid tumours. This strategic investment round was led by DSW Ventures and marks a significant milestone for the company as it aims to revolutionize cancer therapy by improving drug efficacy through direct oxygen delivery to tumours. This fresh infusion of capital demonstrates confidence in StimOxyGen’s potential to significantly impact the oncology space by advancing their lead candidate that enhances treatment outcomes. This funding will aid in the acceleration of their clinical development processes and drive forward their research initiatives.
Sectors
- Biotechnology
- Healthcare
- Venture Capital
Geography
- United Kingdom – The United Kingdom is relevant as both DSW Ventures and StimOxyGen are based there, and the funding is raised in GBP (£1.5 million).
Industry
- Biotechnology – The article relates to the biotechnology industry as it discusses StimOxyGen's development of a novel cancer therapy.
- Healthcare – The focus on overcoming cancer treatment resistance places the article within the wider healthcare sector.
- Venture Capital – DSW Ventures' role in funding StimOxyGen indicates the involvement of the venture capital industry.
Financials
- £1.5 million – The amount raised by StimOxyGen to advance their cancer therapy.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| StimOxyGen | Target | Company | A spin-out from Ulster University focusing on overcoming cancer treatment resistance. |
| DSW Ventures | Funding Company | Company | A private equity firm that led the £1.5m funding round for StimOxyGen. |
| Ulster University | Spin-out Source | Educational Institution | The educational institution where StimOxyGen originated. |